German Pharma Company Investments on the Rise

That’s the conclusion of a study carried out by the Association of German Chambers of Industry and Commerce (DIHK), whose results were published in business newspaper Handelsblatt. 

The DIHK found that 38 percent of pharma companies plan to invest more in the next twelve months compared with only 25 percent at the start of 2023. Conversely only every fifth company plans lower investment, compared with almost a third in the previous survey. 

The mood is likewise optimistic in the medical technology sector, where 19 percent of firms plan additional investments compared with nine percent at the start of the year. The head of the DIHK, Achim Dercks, says the reason behind the upswing in sentiment is politics. 

“The mood is likely to have improved above all because of several political decisions,” he told Handelsblatt. He specifically cited the introduction of voluntary electronic patient records, that should make it dramatically easier to collect health data in Germany.